Kairos Pharma (KAPA) EPS (Basic) (2023 - 2025)

Kairos Pharma (KAPA) has reported EPS (Basic) for 3 consecutive years, with -$0.08 the latest figure, recorded in Q2 2025.

• For the quarter ending Q2 2025, EPS (Basic) fell 272.91% year-over-year to -$0.08; the trailing twelve-month figure through Jun 2025 stood at -$0.3 (down 64.71% YoY), and the FY2025 full-year result was -$0.3, down 11.41% from the prior year.
• EPS (Basic) retreated to -$0.08 in Q2 2025 per KAPA's latest filing, from -$0.08 in the prior quarter.
• Across five years, EPS (Basic) topped out at -$0.02 in Q2 2024 and bottomed at -$0.14 in Q4 2024.
• Historically, EPS (Basic) has averaged -$0.07 across 3 years, with a median of -$0.08 in 2025.
• The sharpest annual moves came in 2024 and 2025: EPS (Basic) tumbled 32.2% in 2024, then tumbled 272.91% in 2025.
• Over 3 years, EPS (Basic) stood at -$0.11 in 2023, then tumbled by 32.2% to -$0.14 in 2024, then surged by 40.58% to -$0.08 in 2025.
• According to Business Quant data, EPS (Basic) over the past three periods registered -$0.08, -$0.08, and -$0.14 for Q2 2025, Q1 2025, and Q4 2024 respectively.